Link to this page
National Cancer Institute Thesaurus
| Preferred Name | Enzalutamide | |
| Synonyms |
enzalutamide Enzalutamide Benzamide, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-methyl- ENZALUTAMIDE ASP9785 MDV3100 Xtandi |
|
| Definitions |
An orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Through a mechanism that is reported to be different from other approved AR antagonists, enzalutamide inhibits the activity of prostate cancer cell ARs, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum prostate specific antigen (PSA) level. AR over-expression in prostate cancer represents a key mechanism associated with prostate cancer hormone resistance. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C71744 |
|
| Accepted_Therapeutic_Use_For |
castration-resistant prostate cancer (CRPC)
|
|
| CAS_Registry |
915087-33-1
|
|
| Chemical_Formula |
C21H16F4N4O2S
|
|
| code |
C71744
|
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C192234 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173381 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173383 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC HemOnc OORO
|
|
| DEFINITION |
An orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Through a mechanism that is reported to be different from other approved AR antagonists, enzalutamide inhibits the activity of prostate cancer cell ARs, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum prostate specific antigen (PSA) level. AR over-expression in prostate cancer represents a key mechanism associated with prostate cancer hormone resistance.
|
|
| Display_Name |
Enzalutamide
|
|
| FDA_UNII_Code |
93T0T9GKNU
|
|
| FULL_SYN |
enzalutamide Enzalutamide Benzamide, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-methyl- ENZALUTAMIDE ASP9785 MDV3100 Xtandi
|
|
| Has_Target | ||
| Is_Value_For_GDC_Property | ||
| label |
Enzalutamide
|
|
| Legacy Concept Name |
Selective_Androgen_Receptor_Modulator_MDV3100
|
|
| Maps_To |
Enzalutamide
|
|
| NCI_Drug_Dictionary_ID |
560774
|
|
| PDQ_Closed_Trial_Search_ID |
560774
|
|
| PDQ_Open_Trial_Search_ID |
560774
|
|
| Preferred_Name |
Enzalutamide
|
|
| prefixIRI |
Thesaurus:C71744
|
|
| Semantic_Type |
Pharmacologic Substance
|
|
| UMLS_CUI |
C2348174
|
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |